Phase II study of lapatinib and tegafur combination efficacy for the treatment of HER2+metastatic breast cancer.

被引：0
|
作者：
Manikhas, Alexey
Sharvashidze, Ineza O.
Kotkova, Tatjana N.
机构：
[1] City Clin Oncol Dispensary, St Petersburg, Russia
[2] State Clin Oncol Dispensary, St Petersburg, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11086
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
    Devika Gajria
    Joseph Gonzalez
    Kimberly Feigin
    Sujata Patil
    Carol Chen
    Maria Theodoulou
    Pamela Drullinsky
    Gabriella D’Andrea
    Diana Lake
    Larry Norton
    Clifford A. Hudis
    Tiffany A. Traina
    Breast Cancer Research and Treatment, 2012, 131 : 111 - 116
  • [22] Phase II trial of lapatinib for brain metastases in patients with HER2+breast cancer.
    Lin, N. U.
    Carey, L. A.
    Liu, M. C.
    Younger, J.
    Come, S. E.
    Bullitt, E.
    Van den Abbeele, A. D.
    Li, X.
    Hochberg, F. H.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 3S - 3S
  • [23] HIT: A multicenter phase I-II study of trastuzumab administered by intrathecal injection for leptomeningeal meningitis of HER2+metastatic breast cancer.
    Gutierrez, Maya
    Fourme, Emmanuelle
    Taillibert, Sophie
    Le Rhun, Emilie
    Tredan, Olivier
    Gunzer, Katharina
    Dieras, Veronique
    Mefti, Fawzia
    Vago-Ady, Nora
    Tresca, Patricia
    Turbiez, Isabelle
    Paintaud, Gilles
    Brain, Etienne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
    Barr, J. A.
    Sharma, P.
    Fabian, C. J.
    Yeh, H.
    Baccaray, S.
    Springer, M.
    Khan, Q. J.
    CANCER RESEARCH, 2016, 76
  • [25] A phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
    Rooney, Anthony
    Sharma, Priyanka
    O'Dea, Anne P.
    Nye, Lauren
    Elia, Manana
    He, Jianghua
    Fabian, Carol
    Khan, Qamar
    CANCER RESEARCH, 2022, 82 (04)
  • [26] Phase II trial of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer.
    Kang, Irene
    Spicer, Darcy V.
    Lu, Janice M.
    Groshen, Susan G.
    Tsao-Wei, Denice
    Garcia, Agustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Larotaxel (L) in combination with trastuzumab in patients with HER2+metastatic breast cancer (MBC): Interim analysis of an open phase II label study
    Dieras, V.
    Viens, P.
    Veyret, C.
    Romieu, G.
    Awada, A.
    Lidbrink, E.
    Bonnefoi, H.
    Mery-Mignard, D.
    Dalenc, F.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Bevacizumab plus trastuzumab for treatment of HER2+metastatic breast cancer
    De Amuriza Chicharro, N.
    Gastalver Martin, C.
    Goyache Goni, M. P.
    Cortijo Cascajares, S.
    Garcia Munoz, C.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 984 - 985
  • [29] ORAL TEGAFUR IN THE TREATMENT OF METASTATIC BREAST-CANCER - A PHASE-II STUDY
    KAJANTI, MJ
    PYRHONEN, SO
    MAICHE, AG
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (06) : 863 - 866
  • [30] An Evaluation of the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2+Metastatic Breast Cancer
    Esteva, F. J.
    Franco, S. X.
    Hagan, M. K.
    Somer, R. A.
    Dombroski, C. S.
    Florance, A. M.
    Turner, S. J.
    Stein, S.
    Perez, A.
    CANCER RESEARCH, 2009, 69 (24) : 793S - 793S
12345